Toni Choueiri: New standard of care for high-risk locally advanced cervical cancer

Toni Choueiri shared a post on X:

”New standard of care for high-risk locally advanced cervical cancer (LACC)?

The phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study shows that the addition of pembrolizumab to concurrent chemoradiotherapy (CCRT) leads to a significant and clinically meaningful improvement in overall survival (OS) with a manageable safety profile!”

Source: Toni Choueiri/X

Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.